Osimertinib: Overall Survival Data Published for EGFR-Mutated Advanced NSCLC

By Hipa.ai Research · January 1, 2025

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 18, 2026.

New overall survival data involving osimertinib (Tagrisso) in EGFR-mutated advanced non-small cell lung cancer (NSCLC) was published on 2025-01-01. The publication details results from the MARIPOSA study, which compared amivantamab and lazertinib combination therapy against osimertinib.

Background

Osimertinib is an established treatment for patients with EGFR-mutated advanced NSCLC. The publication of overall survival data is a significant event for clinicians and researchers, as it provides crucial insights into long-term patient outcomes and comparative efficacy within this specific cancer type. The MARIPOSA study, as indicated by its summary, investigated a combination therapy as a potential alternative or advancement over existing treatments like osimertinib.

Trial design

The published data pertains to the MARIPOSA study, which was designed as a comparison of amivantamab and lazertinib combination therapy versus osimertinib. This study focused on patients with locally advanced or metastatic non-small cell lung cancer that is EGFR-mutated, aiming to evaluate the relative efficacy of the investigational combination against osimertinib as a comparator.

What this means

The publication of overall survival data from the MARIPOSA study provides important information for the treatment landscape of EGFR-mutated advanced NSCLC. While osimertinib served as a comparator arm in this study, the availability of these results contributes to the broader understanding of treatment effectiveness and patient prognosis in this challenging disease. Clinicians and researchers can now analyze these long-term outcomes to inform treatment decisions and future research directions for patients with EGFR-mutated advanced NSCLC.

Source

The information regarding the overall survival data involving osimertinib was published on 2025-01-01 in the New England Journal of Medicine, as sourced via PubMed. The publication is titled "Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC" and can be accessed on pubmed.ncbi.nlm.nih.gov.